VWR Acquires MESM Ltd.

/in , /by

Acquisition further expands VWRCATALYST Services for Clinical Trial Studies RADNOR, Pa. — VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, announced today that it has acquired MESM Ltd., a provider of laboratory and medical equipment and ancillary supplies to clinical trials worldwide. Widely respected by customers for its ability […]

Read more →

LGC acquires Axolabs and invests in GMP manufacturing capacity for therapeutic nucleic acids

/in , , /by

LGC today announced that it has acquired Axolabs, a leading Contract Research, Development and Manufacturing Organisation, specialising in the development of therapeutic nucleic acids  (TNAs). LGC also announced a major investment at its Biosearch subsidiary in Petaluma, California, USA to expand its GMP oligonucleotide manufacturing capacity to provide TNA synthesis to the 1kg scale in […]

Read more →

VWR Acquires EPL Archives, Inc.

/in , , /by

Acquisition will Expand VWRCATALYST Services Portfolio RADNOR, Pa. — VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, announced today that it has acquired EPL Archives, Inc., an international biorepository services organization that supports customers across the entire regulated product research, development and commercialization lifecycle by providing archive […]

Read more →

Lexogen Launches Quantitative RNA-Seq Service for Cost-efficient and Accurate Gene Expression Profiling

/in , , , , /by

Austria – Today Lexogen, a transcriptomics and next generation sequencing company, announces the start of its RNA-Seq service, which focuses on gene expression profiling using Lexogen’s proprietary QuantSeq technology. Lexogen’s QuantSeq 3’ mRNA-Seq Library Prep Kit has already been recognized as one of the fastest, most cost-efficient, and accurate methods for expression profiling using next […]

Read more →

Horizon Discovery Signs a Master Service Agreement with a Top Three Pharmaceutical Company

/in , , , /by

Cambridge, UK: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the world leader in the application of gene editing technologies, today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company (the “Company”), extending support for their drug discovery and development efforts to Horizon’s full suite of […]

Read more →